Multiple Sourcing Framework Contracts to Speed up the Development of and Access to Innovative Medical Countermeasures: Next-Generation Influenza Vaccines

This call for tenders aims to accelerate the development of next-generation influenza vaccines that can be produced in rapidly scalable manufacturing platforms (e.g., nucleic acid approaches, scalable eukaryotic or bacterial cell culture, plants, or in vitro transcription). The vaccines should support novel administration routes (e.g., nasal, oral, or microneedle patches), confer mucosal immunity, target potentially pandemic influenza A viruses, be rapidly adaptable to pandemic strains, provide protection across influenza subtypes or alpha-influenza viruses, and/or possess intrinsic immunogenicity without adjuvants. The call will be implemented through a competitive phased development under Pre-Commercial Procurement.